Autotelic Bio
San Diego, California, United States · Biotechnology, Health Care, Pharmaceutical
Autotelic Bio is an RNA innovative drug developer focused on creating treatments for hypertension and diabetes. They have developed ATB-101, a combination drug that operates on a modular platform, capable of expanding into various pipelines. The company has recently received FDA approval for the Phase 1 clinical trial of ATB-101 in the US market. They are in the process of securing funding for the
Key facts
- Headquarters
- San Diego, California, United States
- Employees
- 13
- Industries
- Biotechnology, Health Care, Pharmaceutical
- Status
- Private
- Website
- autotelic.co.kr
- Company page
Recent activity at Autotelic Bio
Autotelic Bio funding history
| Date | Round | Amount |
|---|---|---|
| Jun 2026 | Series B | Undisclosed |
Leadership
- Chris, Managing Director / Head of Global Business Development
Verified email and direct lines for Autotelic Bio’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Companies similar to Autotelic Bio
- Lavior Pharma · Biotechnology, Health Care, Pharmaceutical
- TNF Pharmaceuticals · Biotechnology, Health Care, Pharmaceutical
- Nintx · Biotechnology, Health Care, Pharmaceutical
- LTR Pharma Limited · Biotechnology, Health Care, Pharmaceutical
- Sagimet · Biotechnology, Health Care, Pharmaceutical
About Autotelic Bio: questions and answers
What does Autotelic Bio do?
Autotelic Bio is an RNA innovative drug developer focused on creating treatments for hypertension and diabetes. They have developed ATB-101, a combination drug that operates on a modular platform, capable of expanding into various pipelines. The company has recently received FDA approval for the Phase 1 clinical trial of ATB-101 in the US market. They are in the process of securing funding for the
Where is Autotelic Bio headquartered?
Autotelic Bio is headquartered in San Diego, California, United States.
How many employees does Autotelic Bio have?
Autotelic Bio has about 13 employees.
Has Autotelic Bio raised funding?
Yes. Fundz has recorded 1 funding event for Autotelic Bio. The most recent, Series B of Undisclosed, was in Jun 2026.
What is the latest news on Autotelic Bio?
On Jun 29, 2026, Autotelic Bio has successfully closed its Series B Bridge round with investments from Kiwoom Securities and others. This round is crucial for their upcoming IPO and ongoing drug development efforts.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy